BRPI0811112A2 - Uso de inibidores de hdac para o tratamento de cânceres gastrointestinais. - Google Patents

Uso de inibidores de hdac para o tratamento de cânceres gastrointestinais.

Info

Publication number
BRPI0811112A2
BRPI0811112A2 BRPI0811112-0A2A BRPI0811112A BRPI0811112A2 BR PI0811112 A2 BRPI0811112 A2 BR PI0811112A2 BR PI0811112 A BRPI0811112 A BR PI0811112A BR PI0811112 A2 BRPI0811112 A2 BR PI0811112A2
Authority
BR
Brazil
Prior art keywords
treatment
hdac inhibitors
gastrointestinal cancers
cancers
gastrointestinal
Prior art date
Application number
BRPI0811112-0A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Peter Wisdom Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39683987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0811112(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0811112A2 publication Critical patent/BRPI0811112A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0811112-0A2A 2007-05-04 2008-05-02 Uso de inibidores de hdac para o tratamento de cânceres gastrointestinais. BRPI0811112A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91599607P 2007-05-04 2007-05-04
PCT/US2008/062341 WO2008137630A1 (en) 2007-05-04 2008-05-02 Use of hdac inhibitors for the treatment of gastrointestinal cancers

Publications (1)

Publication Number Publication Date
BRPI0811112A2 true BRPI0811112A2 (pt) 2014-12-23

Family

ID=39683987

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811112-0A2A BRPI0811112A2 (pt) 2007-05-04 2008-05-02 Uso de inibidores de hdac para o tratamento de cânceres gastrointestinais.

Country Status (16)

Country Link
EP (1) EP2142190A1 (xx)
JP (1) JP2010526149A (xx)
KR (1) KR20100016171A (xx)
CN (1) CN101674825A (xx)
AU (1) AU2008247603A1 (xx)
BR (1) BRPI0811112A2 (xx)
CA (1) CA2683554A1 (xx)
CL (1) CL2008001269A1 (xx)
IL (1) IL201318A0 (xx)
MA (1) MA31356B1 (xx)
MX (1) MX2009011692A (xx)
RU (1) RU2009144842A (xx)
TN (1) TN2009000427A1 (xx)
TW (1) TW200908964A (xx)
WO (1) WO2008137630A1 (xx)
ZA (1) ZA200906739B (xx)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20070167499A1 (en) * 2003-10-27 2007-07-19 A*Bio Pte Ltd. Biaryl linked hydroxamates: preparation and pharmaceutical applications
EP1685094A4 (en) * 2003-10-27 2007-08-22 S Bio Pte Ltd HYDROXAMATES CONNECTED TO ACYLUREE AND SULFONYLUREE
WO2006075165A1 (en) * 2005-01-13 2006-07-20 Btg International Limited Combination of oncolytic viruses with angiogenesis inhibitors

Also Published As

Publication number Publication date
TW200908964A (en) 2009-03-01
RU2009144842A (ru) 2011-06-10
IL201318A0 (en) 2010-05-31
KR20100016171A (ko) 2010-02-12
CA2683554A1 (en) 2008-11-13
WO2008137630A1 (en) 2008-11-13
CN101674825A (zh) 2010-03-17
CL2008001269A1 (es) 2008-12-19
MA31356B1 (fr) 2010-05-03
MX2009011692A (es) 2009-11-10
ZA200906739B (en) 2010-06-30
TN2009000427A1 (en) 2011-03-31
AU2008247603A1 (en) 2008-11-13
EP2142190A1 (en) 2010-01-13
JP2010526149A (ja) 2010-07-29

Similar Documents

Publication Publication Date Title
NL301192I2 (nl) Finerenon en zijn zouten, solvaten en solvaten van de zouten daarvan
CY2017016I2 (el) Αναστολεις πρωτεασωματος
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0822560A2 (pt) Instrumento para aplicações endoscópicas ou semelhantes
BRPI0818320A2 (pt) composição para tratamento de câncer de próstata (pca)
BRPI0817096A2 (pt) análogos de tiazolidinodiona para o tratamento de hipertensão
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI0719204A2 (pt) Inibidores de hdac
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI0817870A2 (pt) dispositivo para tratamento de aneurisma
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0811752A2 (pt) Aparelho para tratar gás
BRPI0912683A2 (pt) tratamento de tumores metastáticos
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BRPI0910780A2 (pt) uso de antagonistas de opióides para o tratamento da retenção urinária
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
BRPI0810207A2 (pt) Métodos e composições para o tratamento de câncer
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
BRPI0911515A2 (pt) dispositivos formadores rotatórios e métodos para o uso de tais dispositivos.
BRPI0907956A2 (pt) Uso de ranolazina para o tratamento de doenças cardiovasculares
BRPI0821100A2 (pt) composições e métodos para o tratamento de câncer de bexiga

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.